In the article “Identification of circulating MOG-specific B cells in patients with MOG antibodies” by Winklmeier et al.,1 first published online October 14, 2019, on the right side panel in figure 2a, the labelling of patient 15 should not have been included while the labelling of patient 26b should have been included. The corrected figure appears below. The publisher and the authors regret the error.
- © 2019 American Academy of Neurology
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
Dimethyl fumarate as a first- vs second-line therapy in MS
Identification of circulating MOG-specific B cells in patients with MOG antibodies